Clinical Trial Update: Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase II study investigating KW2871 with high-dose Interferon-α2b in metastatic/cutaneous melanoma completed with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Interferon-α2b (high dose) (Interferon-alpha-2b)
• KW2871

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Metastatic Melanoma, Cutaneous Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2018-02-09